Abbot announces definitive contract to obtain STARLIMS Technologies for $123 million Abbott announced today a definitive contract to acquire STARLIMS Systems Ltd ed pills . , a respected provider of laboratory info management systems, for approximately $123 million in money. The acquisition strengthens Abbott’s competitive placement in the global diagnostics marketplace, providing advanced web-structured applications to help laboratories efficiently store, retrieve and analyze a significantly increasing level of clinical, managerial and administrative data.
Market because of medical trial data indicating an increased risk of heart stroke and attack, the U.S. Today Food and Drug Administration announced. Meridia’s continued availability isn’t justified when you compare the very modest weight loss that people achieve upon this medication to their threat of heart attack or stroke, stated John Jenkins, M.D., director of any office of New Drugs in the FDA’s Middle for Medication Evaluation and Analysis . Physicians are advised to stop prescribing Meridia with their patients and patients should stop acquiring this medication. Patients should talk to their doctor about alternative weight loss and weight loss maintenance programs.